Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.

@article{Bytzer2013AnalysisOU,
  title={Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.},
  author={Peter Bytzer and Stuart J. Connolly and Sean T. Yang and Michael Ezekowitz and Stephan Formella and Paul A. Reilly and James Aisenberg},
  journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
  year={2013},
  volume={11 3},
  pages={
          246-52.e1-5
        }
}
BACKGROUND & AIMS Dabigatran is an oral and direct inhibitor of thrombin. In a study of patients with atrial fibrillation (the RE-LY trial), twice as many subjects given dabigatran reported dyspepsia-like symptoms compared with those given warfarin (controls). We analyzed data from this trial to quantify upper gastrointestinal nonbleeding adverse events (NB-UGI AEs). METHODS We analyzed the AE database from the RE-LY trial (18,113 subjects) and assigned NB-UGI AEs to 4 groups: those… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints

VIEW 7 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations

  • Yishen Wang, Beata V Bajorek
  • Medicine
  • American Journal of Cardiovascular Drugs
  • 2014
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran

VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

DDDT_A_203112 1527..1533

VIEW 1 EXCERPT
CITES BACKGROUND